Proenza A M, Poissonnet C M, Ozata M, Ozen S, Guran S, Palou A, Strosberg A D
Institut Cochin de Génétique Moléculaire, Laboratoire d'ImmunoPharmacologie Moléculaire, CNRS UPR 0415 and Université de Paris VII 22, rue Méchain, 75014 Paris, France.
Int J Obes Relat Metab Disord. 2000 Jan;24(1):93-100. doi: 10.1038/sj.ijo.0801091.
OBJECTIVE: To investigate the relationship between the polymorphisms of the beta3-AR (Trp64Arg), UCP1 (A-->G) and LPL (HindIII and PvuII) loci and the metabolic complications associated with obesity in a Turkish population. SUBJECTS: 271 unrelated individuals of Turkish origin including obese (body mass index, BMI>30 kg¿m2) and lean (BMI< or =25 kg¿m2) subjects. MEASUREMENTS: Anthropometric (weight, height and blood pressure) and metabolic measurements (plasma levels of glucose, cholesterol and triglycerides), and determination of beta3-AR, UCP1 and LPL genotypes by polymerase chain reaction followed by enzymatic digestion. RESULTS: The distributions of genotypes for each candidate gene (beta3-AR, UCP1 and LPL) were similar between the obese and the lean subjects. The Arg64 allele of the beta3-AR gene was absent from massively obese men. GG carriers of the A-->G variant of the UCP1 gene showed BMI-associated increases of cholesterol levels which were more marked than both AA (P=0.027) and AG (P=0.039) carriers. Obese P+ carriers of the LPL PvuII variant had significantly higher levels of glucose than non-carriers (P=0.011), whereas obese P+P+ carriers did not have significantly different levels of triglycerides than non-carriers (P=0.087). Moreover, carriers of both alleles (G&P+) had higher levels of glucose than non-carriers (P=0.048), but did not have significantly different levels of triglycerides than non-carriers (P=0.125). However, the BMI-associated increase of triglycerides of P+&G carriers was significantly more marked than that of P+ carriers (P=0.0085). CONCLUSION: Our data support the idea that alleles of specific genes (UCP1, LPL and beta3-AR) might play a role in the development of certain metabolic complications of obesity and might have additive effects when combined with each other (as in the case of UCP1 and LPL). International Journal of Obesity (2000)24, 93-100
目的:在土耳其人群中研究β3 - 肾上腺素能受体(Trp64Arg)、解偶联蛋白1(UCP1,A→G)和脂蛋白脂肪酶(LPL,HindIII和PvuII)基因座多态性与肥胖相关代谢并发症之间的关系。 对象:271名具有土耳其血统的无亲缘关系个体,包括肥胖(体重指数,BMI>30 kg·m²)和消瘦(BMI≤25 kg·m²)个体。 测量指标:人体测量学指标(体重、身高和血压)和代谢指标(血浆葡萄糖、胆固醇和甘油三酯水平),通过聚合酶链反应随后酶切来确定β3 - 肾上腺素能受体、UCP1和LPL基因的基因型。 结果:肥胖和消瘦个体中每个候选基因(β3 - 肾上腺素能受体、UCP1和LPL)的基因型分布相似。β3 - 肾上腺素能受体基因的Arg64等位基因在极度肥胖男性中不存在。UCP1基因A→G变异的GG携带者显示胆固醇水平与BMI相关升高,比AA(P = 0.027)和AG(P = 0.039)携带者更明显。LPL PvuII变异的肥胖P +携带者的葡萄糖水平显著高于非携带者(P = 0.011),而肥胖P + P +携带者的甘油三酯水平与非携带者无显著差异(P = 0.087)。此外,两个等位基因(G&P +)的携带者的葡萄糖水平高于非携带者(P = 0.048),但甘油三酯水平与非携带者无显著差异(P = 0.125)。然而,P + &G携带者的甘油三酯与BMI相关的升高比P +携带者更明显(P = 0.0085)。 结论:我们的数据支持特定基因(UCP1、LPL和β3 - 肾上腺素能受体)的等位基因可能在肥胖某些代谢并发症的发生中起作用,并且相互组合时可能具有累加效应(如UCP1和LPL的情况)。《国际肥胖杂志》(2000年)24卷,93 - 100页
Clin Chem Lab Med. 2004-5
Int J Obes Relat Metab Disord. 2000-10
BMC Med Genet. 2018-11-20
Cardiovasc Diabetol. 2011-10-12